This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Filter 392,441 trials Clear all
Filter by:

Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

  • Status Not yet recruiting
    Not yet recruiting
  • Condition HNSCC
    HNSCC
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Camrelizumab

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Camrelizumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Cancer hospital, Chineses Academy of Medical Sciences, Beijing, China

Brief Summary

The purpose of this study was to evaluate the efficacy and safety of Camrelizumab as maintenance therapy in newly diagnosed locally advanced head and neck squamous cell carcinoma subjects after chemoradiation.

The Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor

  • Status Not yet recruiting
    Not yet recruiting
  • Condition Advanced Solid Tumor
    Advanced Solid Tumor
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: TWP-101

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: TWP-101

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

Brief Summary

This is a multi-center, phase Ia/Ib, open clinical study to evaluate the safety and efficacy of TWP-101 in patients with advanced solid tumor. This study consists of two parts (Part A and Part B). Part A was a dose escalation study, and Part B was a dose expansion study.

The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage II

  • Status Not yet recruiting
    Not yet recruiting
  • Condition Esophageal Cancer, Gastric Cancer, Lung Cancer
    Esophageal Cancer, Gastric Cancer, Lung Cancer
  • Phase Phase 3
    Phase 3
INTERVENTION

Dietary Supplement: Vitamin D3 Drops, Dietary Supplement: Coriolus Versicolor, Dietary Supplement: Trident SAP 66:33 Lemon, Dietary Supplement: Probiotic Pro12, Dietary Supplement: Provitalix Pure Whey Protein, Dietary Supplement: Theracurmin 2X, Dietary Supplement: Green Tea Extract, Other: Nutrition Recommendations, Other: Physical Activity Recommendations, Behavioral: Psychological Recommendations

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Dietary Supplement: Vitamin D3 Drops, Dietary Supplement: Coriolus Versicolor, Dietary Supplement: Trident SAP 66:33 Lemon, Dietary Supplement: Probiotic Pro12, Dietary Supplement: Provitalix Pure Whey Protein, Dietary Supplement: Theracurmin 2X, Dietary Supplement: Green Tea Extract, Other: Nutrition Recommendations, Other: Physical Activity Recommendations, Behavioral: Psychological Recommendations

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

The Ottawa Hospital, Ottawa, Ontario, Canada

Brief Summary

Despite enormous advances in thoracic surgery and oncology, two critical issues concern patients undergoing curative-intent surgery for lung, gastric and esophageal cancer: first, a majority (~60%) of patients experience minor and major adverse events occurring during and in the days following surgery; second, patients worry about the significant risk of cancer recurrence and mortality months to years after surgery. These issues, combined with side effects of chemotherapy and radiation, have detrimental effects on health-related quality of life (HRQoL). On a deeper level, there is the problem of an ongoing failure to integrate and evaluate the best of what complementary medicine has to offer surgical oncology care. Too many clinical trials focus on single agent therapies, rather than broad multi-faceted individualized and integrative care interventions that are used in real world settings. The Thoracic POISE project has the overarching goal of improving care for thoracic cancer patients by impacting HRQoL, reducing surgical adverse events, prolonging overall survival and pioneering integrative care delivery.

Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment

  • Status Recruiting
    Recruiting
  • Condition Tobacco Use Disorder, Smoking Cessation
    Tobacco Use Disorder, Smoking Cessation
  • Phase Phase 2 Phase 3
    Phase 2 Phase 3
INTERVENTION

Drug: EMB-01

Eligibility
  • Ages: 21 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: EMB-01

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Rose Research Center, Raleigh, North Carolina, United States

Brief Summary

This open-label study will evaluate EMB-001, comprised of metyrapone, a cortisol synthesis inhibitor marketed as a diagnostic drug for testing hypothalamic-pituitary-adrenal (HPA) axis function, combined with oxazepam, an anxiolytic and sedative/hypnotic benzodiazepine, to help smokers abstain from smoking during a 12-week trial period.

IBI188 Combination Therapy in Solid Tumors

  • Status Recruiting
    Recruiting
  • Condition Osteosarcoma, Lung Adenocarcinoma, Solid Tumors
    Osteosarcoma, Lung Adenocarcinoma, Solid Tumors
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: IBI188, Drug: GM-CSF, Drug: Cisplatin/Carboplatin, Drug: Bevacizumab, Drug: Sintilimab, Drug: Pemetrexed

Eligibility
  • Ages: 12 Years and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: IBI188, Drug: GM-CSF, Drug: Cisplatin/Carboplatin, Drug: Bevacizumab, Drug: Sintilimab, Drug: Pemetrexed

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Brief Summary

A Phase Ib study aim to explore the efficacy, safety, and tolerability of IBI188 combination therapy in subjects with advanced malignancies

Study of a Live rNDV Based Vaccine Against COVID-19

  • Status Recruiting
    Recruiting
  • Condition SARS-CoV-2 Infection
    SARS-CoV-2 Infection
  • Phase Phase 1
    Phase 1
INTERVENTION

Biological: Recombinant NDV Vectored Vaccine for SARS-CoV-2

Eligibility
  • Ages: 18 to 55 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Biological: Recombinant NDV Vectored Vaccine for SARS-CoV-2

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Hospital Medica Sur, Mexico City, Ciudad De Mexico, Mexico

Brief Summary

This is a Phase 1, open-label, non-randomized, dose-escalation study using three doses and two schemes of administration of a recombinant vaccine against SARS-CoV-2 based on a viral vector (Newcastle Disease virus) in 90 healthy volunteers at a single research site in Mexico City.

Pharmacokinetics and Pharmacodynamics of Mycophenolate Mofetil in Pediatric Hematopoietic Stem Cell Transplantation

  • Status Recruiting
    Recruiting
  • Condition Hematopoietic Stem Cell Transplantation
    Hematopoietic Stem Cell Transplantation
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: Mycophenolate Mofetil

Eligibility
  • Ages: up to 17 / (Birth to 17 years)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Mycophenolate Mofetil

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Seoul National University Hospital, Seoul, Korea, Republic of

Brief Summary

This is an investigator-initiated clinical trial to analysis population pharmacokinetic characteristics and investigate appropriate pediatric dose of mycophenolate mofetil in pediatric hematopoietic stem cell transplantation patients.

A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19

  • Status Recruiting
    Recruiting
  • Condition Covid19
    Covid19
  • Phase Phase 2
    Phase 2
INTERVENTION

Biological: Ampion, Other: Placebo

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: Ampion, Other: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Ampio Pharmaceuticals, Englewood, Colorado, United States

Brief Summary

This is phase II study to evaluate the safety and efficacy of inhaled Ampion in adults with respiratory distress due to COVID-19

A Study of BTX-A51 in People With Advanced Solid Tumor or Non-Hodgkin Lymphoma

  • Status Recruiting
    Recruiting
  • Condition Non Hodgkin Lymphoma, Advanced Solid Tumor
    Non Hodgkin Lymphoma, Advanced Solid Tumor
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: BTX-A51

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: BTX-A51

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Florida Cancer Specialists, Sarasota, Florida, United States

Brief Summary

This is a multicenter, open label, nonrandomized, sequential dose escalation/cohort expansion, multiple dose study designed to evaluate the safety, toxicity, and PK as well as preliminary efficacy of BTX-A51 in subjects with advanced solid tumors and NHL. The study will be done in two phases, described below. Phase 1a (Dose Escalation Phase): The Phase 1a portion is designed to determine the dose limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of orally administered BTX-A51. BTX-A51 will be administered once daily on a weekly schedule of 5 days on/2 days off. Dose escalation will proceed according to a modified 3+3 design. Each cycle will consist of 28 days (4 weeks), and the DLT observation period will be the first cycle (i.e., 28 days after initiation of dosing). A DLT may be observed in no more than 0 out of 3 or 1 out of 6 subjects who have completed the DLT observation period before the next cohort initiates accrual. Barring DLT, sequential dose escalation of BTX-A51 is planned with up to a total of 6 dose levels; on the basis of these an MTD will be identified. The MTD is defined as the highest dose level with a subject incidence of DLTs of 0 or 1 out of 6 during the first 28 days of study drug dosing. A minimum of 6 subjects needs to be treated at a dose level before this dose level can be deemed as the MTD. Phase 1b (Cohort Expansion Phase): Dose expansion may begin when the RP2D has been determined. Up to 40 additional subjects will be enrolled to evaluate safety and preliminary efficacy of BTX-A51 in subjects with documented MYC genomic amplified/overexpressed tumors. Dosing in this phase of the study consists of the first cycle of therapy (i.e., 28 days).

Dermaprazole Cream for Radiation Dermatitis in Definitive Head and Neck Cancer

  • Status Not yet recruiting
    Not yet recruiting
  • Condition Cancer of the Head and Neck
    Cancer of the Head and Neck
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Dermaprazole, Drug: Aquaphor

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Dermaprazole, Drug: Aquaphor

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

In this study, the study team seek to conduct a pilot clinical study to evaluate the safety and efficacy of a reformulated proton pump inhibitor (PPI) cream (Dermaprazole) in definitive head and neck cancer (HNC) patients.